Literature DB >> 10487683

Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study.

P Arikoski1, J Komulainen, P Riikonen, R Voutilainen, M Knip, H Kröger.   

Abstract

In the present study, longitudinal changes in bone mineral density, bone turnover, and bone hormonal metabolism were evaluated in newly diagnosed children with cancer. Lumbar spine (L2-L4) and femoral neck bone mineral densities (grams per cm2) were measured by dual energy x-ray absorptiometry in 28 children (age, 2.9-16.0 yr; median, 8.0 yr; 10 acute lymphoblastic leukemias, 18 solid tumors) at diagnosis and after a 1-yr follow-up. Apparent volumetric density (grams per cm3) was calculated to minimize the effect of bone size on BMD. Serum levels of osteocalcin (OC), type I collagen carboxyl-terminal propeptide (PICP), and type I collagen carboxyl-terminal telopeptide were measured serially during the study. Serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, insulin-like growth factor I (IGF-I), and IGF-binding protein-3 were analyzed at diagnosis and at 1-yr follow-up. A significant decrease in femoral bone mineral density and apparent volumetric density was observed during the year after diagnosis [(mean (SD), -10.1% (8.8%) and -11.3% (8.1%) respectively; P < 0.01], whereas age- and sex-matched controls showed annual increments of +5.4% (7.7%; P < 0.01) and +0.7% (5.7%; P = NS) respectively. The markers of bone formation (PICP and OC) were significantly decreased at diagnosis. By the end of the follow-up, PICP and OC were normalized, whereas the marker of bone resorption (type I collagen carboxyl-terminal telopeptide) was significantly increased. Reduced levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and IGF-binding protein-3 were observed during the study. To conclude, increased bone resorption and impaired development of femoral bone density were observed in children with cancer during chemotherapy. Deficient accumulation of bone mass may lead to impaired development of peak bone mass and predispose children with cancer to increased risk of osteoporosis and diminished skeletal resistance to fractures later in life.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487683     DOI: 10.1210/jcem.84.9.5968

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma.

Authors:  Ulrike Michaela Pirker-Frühauf; Jörg Friesenbichler; Ernst-Christian Urban; Barbara Obermayer-Pietsch; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2012-07-18       Impact factor: 4.176

2.  Chemotherapy Curtails Bone Formation From Compliant Compression Fixation of Distal Femoral Endoprostheses.

Authors:  Mohammad A Elalfy; Patrick J Boland; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2019-01       Impact factor: 4.176

3.  Bone density in post-pubertal adolescent survivors of childhood brain tumors.

Authors:  Laurie E Cohen; Joshua H Gordon; Erica Y Popovsky; Nina N Sainath; Henry A Feldman; Mark W Kieran; Catherine M Gordon
Journal:  Pediatr Blood Cancer       Date:  2011-08-29       Impact factor: 3.167

4.  Bone mineral density in survivors of childhood brain tumours.

Authors:  M Petraroli; E D'Alessio; E Ausili; A Barini; P Caradonna; R Riccardi; M Caldarelli; A Rossodivita
Journal:  Childs Nerv Syst       Date:  2006-10-13       Impact factor: 1.475

5.  Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.

Authors:  Ahmed Megahed; Nanees Salem; Abeer Fathy; Tarik Barakat; Mona Abd El Latif Alsayed; Suzy Abd El Mabood; Khaled R Zalata; Ahmed F Abdalla
Journal:  World J Pediatr       Date:  2017-01-27       Impact factor: 2.764

6.  Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia.

Authors:  E Orgel; N M Mueske; T A L Wren; V Gilsanz; A M Butturini; D R Freyer; S D Mittelman
Journal:  Bone       Date:  2016-02-03       Impact factor: 4.398

7.  Systematic review of the effects of bisphosphonates on bone density and fracture incidence in childhood acute lymphoblastic leukaemia.

Authors:  A M Harris; A R Lee; S C Wong
Journal:  Osteoporos Int       Date:  2019-08-03       Impact factor: 4.507

8.  Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design.

Authors:  Shesh N Rai; Melissa M Hudson; Elizabeth McCammon; Laura Carbone; Francis Tylavsky; Karen Smith; Harriet Surprise; John Shelso; Chin-Hon Pui; Sue Kaste
Journal:  Contemp Clin Trials       Date:  2008-05-18       Impact factor: 2.226

9.  Do long term survivors of ewing family of tumors experience low bone mineral density and increased fracture risk?

Authors:  Gerhard M Hobusch; Iris Noebauer-Huhmann; Christoph Krall; Gerold Holzer
Journal:  Clin Orthop Relat Res       Date:  2014-07-12       Impact factor: 4.176

10.  An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma.

Authors:  Carmine Zoccali; Umberto Prencipe; Virginia Ferraresi; Nicola Salducca
Journal:  J Orthop Traumatol       Date:  2009-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.